Authors
Emmalene J. Bartlett, Vanessa S. Cull, Eva N. Mowe, Josephine P. Mansfield, Cassandra M. James
Summary
Type I interferon (IFN) gene therapy modulates the immune response leading to inflammatory heart disease following cytomegalovirus (CMV) infection in a murine model of post-viral myocarditis. Efficacy of different immunisation protocols for the IFN constructs was influenced by the dose of DNA, subtype choice, combination use, pre-medication, and timing of DNA administration. Optimal efficacy was found with bupivacaine treatment prior to DNA inoculation of 200µgIFN DNA 14 days prior to virus challenge. Maximal antiviral and antimyocarditic effects were achieved with this vaccination schedule. Furthermore, inoculation of synergistic IFN subtypes demonstrated enhanced efficacy when delivered either alone or with CMVgB DNA vaccination in the CMV model. Thus naked DNA delivery of IFN provides an avenue of immunotherapy for regulating herpesvirus-induced diseases.Further details
The protocol was imported from Springer Protocols. To see the entire protocol, click on the source link, or download the pdf here.Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 263
- Comments 0